Journal: Frontiers in Oncology
Article Title: CIK-augmented anti-PD1/CTLA4 immunotherapy eradicates chemo-resistant ovarian cancer via tripartite mechanistic synergy
doi: 10.3389/fonc.2025.1670033
Figure Lengend Snippet: Effects of different treatments on cell proliferation. (A) Proliferation of A2780 cells under indicated treatments (A2780: untreated cells, A2780+N+I: A2780+Nivolumab+Ipilimumab, A2780+N+I+CIK: A2780+Nivolumab+Ipilimumab+CIK cells. (B) Proliferation of SKOV3 cells under indicated treatments (SKOV3, SKOV3+N+I, SKOV3+N+I+CIK). Cell proliferation was assessed by measuring OD values at 450 nm. n=3, **=0.004, **=0.0006, **=0.002, **=0.0001 vs. control group.
Article Snippet: Immune checkpoint inhibitors Nivolumab (HY-P9903, MCE) and Ipilimumab (HY-P9901, MCE); apoptosis and cell cycle detection kits Annexin V-FITC/PI (CA1020, Solarbio) and DNA Content Assay Kit (CA1510, Solarbio); extracellular matrix component Matrigel (356234, Corning); cell viability reagent CCK-8 Kit (CK04, Dojindo); staining agent Crystal Violet (C8470, Solarbio); and fixation solution 4% Paraformaldehyde (G1113, Servicebio).
Techniques: Control